The editor-in-chief is Martin Pera ( Jackson Laboratory ). The findings underscore the significance of addressing complications and risk factors associated with allogeneic transplantation, including GVHD and infections. It is the official journal of the International Society for Stem Cell Research. This study provides valuable insights into the treatment strategies and patient care of allo-HCT for hematological disorders by offering a comprehensive overview of multiple relevant outcomes. The overall survival rate in this study was 62%, with 79% of patients disease-free on their last visit. Cites per document Year Value Cites / Doc. The two years line is equivalent to journal impact factor (Thomson Reuters) metric. three and four years have been cited in the current year. Sepsis emerged as the primary cause of non-relapsed mortality at day 100 and beyond. Cell Stem Cell publishes research reports describing novel results of unusual significance in all areas of stem cell research. Graft failure occurred in 13 patients, with primary and secondary graft failure rates of 1.6% and 5.5%, respectively. Despite the majority of patients receiving fully matched transplants, Acute GVHD was observed in 30% of the cohort. The most common indications for allo-HCT were benign hematological diseases, particularly aplastic anemia, and thalassemia major. Key outcomes, including indications for transplantation, overall survival, engraftment time, relapse rates, graft-versus-host disease (GVHD), and transplant-related mortality (TRM), were assessed. We conducted a retrospective analysis of 180 patients with hematological diseases who underwent allo-HCT between January 2011 and December 2021. This study aims to evaluate the outcomes of allo-HCT in hematological diseases and identify significant complications in a single-center setting. Allogeneic hematopoietic cell transplantation (allo-HCT) is a complex procedure with the potential to provide curative treatment for various hematological disorders.
0 kommentar(er)
